[go: up one dir, main page]

WO2007076320A3 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
WO2007076320A3
WO2007076320A3 PCT/US2006/062224 US2006062224W WO2007076320A3 WO 2007076320 A3 WO2007076320 A3 WO 2007076320A3 US 2006062224 W US2006062224 W US 2006062224W WO 2007076320 A3 WO2007076320 A3 WO 2007076320A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
arthritis
invented
inhibitors
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/062224
Other languages
French (fr)
Other versions
WO2007076320A2 (en
WO2007076320A8 (en
Inventor
Toshihiro Hamajima
Hiroko Nakamura
Jun Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to EP06840303A priority Critical patent/EP1962851A2/en
Priority to JP2008547704A priority patent/JP2009521490A/en
Publication of WO2007076320A2 publication Critical patent/WO2007076320A2/en
Publication of WO2007076320A3 publication Critical patent/WO2007076320A3/en
Anticipated expiration legal-status Critical
Publication of WO2007076320A8 publication Critical patent/WO2007076320A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Invented are novel azaindole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
PCT/US2006/062224 2005-12-22 2006-12-18 Compounds Ceased WO2007076320A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06840303A EP1962851A2 (en) 2005-12-22 2006-12-18 Compounds
JP2008547704A JP2009521490A (en) 2005-12-22 2006-12-18 Compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75321705P 2005-12-22 2005-12-22
US60/753,217 2005-12-22

Publications (3)

Publication Number Publication Date
WO2007076320A2 WO2007076320A2 (en) 2007-07-05
WO2007076320A3 true WO2007076320A3 (en) 2007-11-29
WO2007076320A8 WO2007076320A8 (en) 2008-07-10

Family

ID=38218788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/062224 Ceased WO2007076320A2 (en) 2005-12-22 2006-12-18 Compounds

Country Status (3)

Country Link
EP (1) EP1962851A2 (en)
JP (1) JP2009521490A (en)
WO (1) WO2007076320A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1979353A2 (en) * 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
EP3173415B1 (en) * 2008-10-09 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Activators of human pyruvate kinase
DE102008052943A1 (en) 2008-10-23 2010-04-29 Merck Patent Gmbh azaindole derivatives
US8546091B2 (en) * 2009-05-22 2013-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy
WO2011137089A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CN112888440A (en) 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Use of Akt inhibitors in ophthalmology
KR20250132936A (en) * 2024-02-29 2025-09-05 한국화학연구원 The new small molecular compounds having IRP2 inhibition activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014808A1 (en) * 1992-12-23 1994-07-07 Farmitalia Carlo Erba Srl Vinylene-azaindole derivatives and process for their preparation
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
US20050256151A1 (en) * 2003-12-24 2005-11-17 Pharmacia Italia S.P.A. Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014808A1 (en) * 1992-12-23 1994-07-07 Farmitalia Carlo Erba Srl Vinylene-azaindole derivatives and process for their preparation
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
US20050256151A1 (en) * 2003-12-24 2005-11-17 Pharmacia Italia S.P.A. Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
WO2007076320A2 (en) 2007-07-05
EP1962851A2 (en) 2008-09-03
JP2009521490A (en) 2009-06-04
WO2007076320A8 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
WO2008098104A8 (en) Inhibitors of akt activity
WO2007058850A3 (en) Inhibitors of akt activity
WO2009158374A3 (en) Inhibitors of akt activity
MXPA06001134A (en) INHIBITORS OF Akt ACTIVITY.
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
AP2139A (en) 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
WO2009158371A8 (en) Inhibitors of akt activity
TW200801008A (en) Protein kinase inhibitors
WO2006015263A3 (en) Lonidamine analogs
WO2007061874A3 (en) Methods and compositions for use in treating cancer
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2008156614A3 (en) Imidazopyrazines as protein kinase inhibitors
IL174952A0 (en) Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2007149482A3 (en) Xanthohumol based protein kinase modulation cancer treatment
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2006113837A3 (en) Inhibitors of akt activity
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
WO2007120333A3 (en) Tetracyclic kinase inhibitors
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
WO2007076320A3 (en) Compounds
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005118592A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006840303

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008547704

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE